GRAIL Stock Gains 7% as Analysts Stay Mixed on Valuation
GRAIL shares rose 7% to roughly $141.85, lifting its market value to $6.24 billion, though volume was well below normal. The stock carries a Hold consensus and a $102.70 average target, even after Canaccord raised its target to $150 with a Buy rating. GRAIL beat quarterly revenue and EPS expectations but remains deeply unprofitable, and insiders have sold about $12.1 million in shares over the past 90 days.
GRAIL's Friday move came on unusually light turnover: about 113,905 shares traded, 88% below its average session. The stock touched $140.81 and closed the prior session at $132.61. Its 50-day average sits near $90.93, while the 200-day average is about $71.59, and beta is 2.83.
Analysts remain divided. Five rate it Buy, six Hold, one Sell; the consensus target is $102.70. Canaccord lifted its target to $150 and kept Buy, while RBC started at Sector Perform with $84 and Mizuho moved to $100 neutral. Quarterly results beat estimates, but net margin was negative 236.95%.
GRAIL's sharp price move and mixed analyst views could affect investors, employees with equity compensation, and patients who may benefit from its medical-technology work. A higher share price may improve access to capital, while insider sales and continued losses could temper confidence. Because the company remains deeply unprofitable, market sentiment